Patent application number | Description | Published |
20100292131 | BIOMARKERS AND METHODS FOR DIAGNOSING, PREDICTING AND/OR PROGNOSING SEPSIS AND USES THEREOF - The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level of at least one further biomarker selected from the group consisting of soluble TNF-receptor 2 (sTNFR2), Pentraxin-3 (PTX-3), Macrophage Colony-Stimulating Factor (MCSF), pro-Brain Natriuretic Protein (pro-BNP), one or more members of the Histone protein family, Procalcitonin (PCT) and c-Reactive Protein (CRP) in a biological sample from said subject, (c) using said measurements obtained in steps (a) and (b) to create a profile for said biomarkers and (d) comparing said profile with a reference biomarker profile obtained form a patient having SIRS or from a healthy subject. | 11-18-2010 |
20110059858 | NEW BIOMARKER FOR DIAGNOSIS, PREDICTION AND/OR PROGNOSIS OF SEPSIS AND USES THEREOF - The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression level of the TREML-1 biomarker as an indication of the condition of the patient, alone or in combination with further sepsis markers. | 03-10-2011 |
20110256169 | NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE - The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis. | 10-20-2011 |
20120034240 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 02-09-2012 |
Patent application number | Description | Published |
20130129750 | PERLECAN AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 05-23-2013 |
20140302509 | PROCATHEPSIN L AND CATHEPSIN L AS BIOMARKERS FOR ISCHEMIA - The present invention relates to procathepsin L, cathepsin L or a fragment thereof as a biomarker for ischemia. The present invention further relates to methods for diagnosing, predicting, prognosticating and/or monitoring ischemia based on measuring said biomarker, and to related kits, devices and uses thereof. | 10-09-2014 |
20140329251 | LTBP2 AS A BIOMARKER FOR LUNG INJURY - The application discloses LTBP2 as a new biomarker for pulmonary injury; methods for the diagnosis, prediction, prognosis and/or monitoring of said pulmonary injury based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 11-06-2014 |
20150045245 | BIOMARKERS AND TEST PANELS USEFUL IN SYSTEMIC INFLAMMATORY CONDITIONS - The application discloses new biomarkers or test panels useful in systemic inflammatory conditions such as sepsis; methods for the diagnosis, prediction, prognosis and/or monitoring systemic inflammatory conditions such as sepsis based on measuring said biomarkers or test panels; and related kits and devices. | 02-12-2015 |